文献速递临床试验与 GCP流行病学与生物统计

2合1适应性设计中治疗效应的估计及其若干扩展

Estimation of treatment effect in 2-in-1 adaptive design and some of its extensions.
PubMed 文献 · Stat Med · 2021-03-15

2合1适应性设计可将II期试验无缝扩展为III期以加速药物研发,但数据驱动的适应性决策给治疗效应估计带来挑战。本文研究了该设计及其扩展中估计的偏倚与方差,并提出偏倚校正估计量,从理论和数值角度研究其性质,为解释治疗效应估计提供指导。

要点

  • 2合1适应性设计存在数据驱动适应性导致的治疗效应估计偏倚。
  • 提出偏倚校正估计量并研究其理论性质。
  • 为正确解释该设计的治疗效应估计提供指导。

核心结论

  • 2合1适应性设计及其扩展中治疗效应估计存在偏倚与方差问题,所提偏倚校正估计量可提供解释指导。

研究设计与样本

  • 方法学研究,聚焦2合1适应性设计及其若干扩展的估计问题。

主要发现

  • 研究了2合1设计及其扩展中估计的偏倚和方差。
  • 提出了若干偏倚校正估计量。
  • 通过理论和/或数值研究进一步探讨了所提估计量的性质。

临床怎么用

  • 为解释2合1适应性设计的治疗效应估计提供指导。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 2-in-1 adaptive design allows seamless expansion of an ongoing Phase II trial into a Phase III trial to expedite a drug development program. Since its publication, it has generated a lot of interest. So far, most of the related research focused on type I error control. Similar to most adaptive designs, 2-in-1 design could also pose a great challenge on estimation of treatment effect due to the data-driven adaptation. In addition, the use of intermediate endpoint for interim adaptive decision-making is a less well-studied field. In this paper, we investigate the bias and variances in estimation for 2-in-1 design and some of its extensions, and propose some bias-adjusted estimators for 2-in-1 design. The properties of the proposed estimators are further studied theoretically and/or numerically, so as to provide guidance on how to interpret the estimated treatment effect of 2-in-1 design.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Li W, Bai X, Deng Q, et al. Estimation of treatment effect in 2-in-1 adaptive design and some of its extensions. Stat Med. 2021. PMID: 33723865. doi:10.1002/sim.8917

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。